Document:

Exhibit
10.2

 

EXECUTION
VERSION

 

VOTING
AGREEMENT

 

This
VOTING AGREEMENT (this “Agreement”), dated as of 7, 2022 (the “Effective Date”), is entered
into between Jupiter Wellness, Inc., a Delaware corporation (the “Company”), and all of the signatories to this agreement
(the “Stockholders”), to which parties may be added after the date hereof. Each of the parties to this Agreement referred
to individually as a “Party” and, jointly, as the “Parties”.

 

WHEREAS,
the Company has entered into an agreement for the acquisition of the shares of common stock of Next Frontier Pharmaceuticals, Inc. (“Next
Frontier Pharmaceuticals”) (the “Next Frontier Acquisition”) through Jupiter Wellness Investments, Inc.,
a Florida corporation and wholly-owned subsidiary of Jupiter Wellness (the “Buyer” and, together with Jupiter Wellness, collectively,
the “Buying Parties”) and related transactions as reflected in that certain First Amended and Restated Stock Purchase
Agreement dated as of January 7, 2022 (the “Purchase Agreement”), by and among Jupiter Wellness, Buyer, Next
Frontier Pharmaceuticals, Next Frontier Holdings, Inc., a Delaware corporation (“NFHI”), and the stockholders listed
on Schedule 1 therein (the “Individual Stockholders”, and together with NFHI, collectively, the “Sellers”);

 

WHEREAS,
pursuant to the terms and subject to satisfaction or waiver of the conditions set forth in the Purchase Agreement, Sellers shall become
majority stockholders of the Company (the “Majority Stockholders”) and will be the beneficial owners of 500,000 shares
of convertible preferred stock of the Company, par value $0.001 per share (the “Common Stock”), representing approximately
60% of the total outstanding pro forma Common Stock on a fully-diluted basis as of the date hereof; and

 

WHEREAS,
as a condition and inducement to enter into the Purchase Agreement, Parent has required that Majority Stockholders and the Management
Team (“Stockholders”) agree, and each Stockholder is willing to agree, to the matters set forth herein; and

 

NOW,
THEREFORE, in consideration of the mutual agreements and understandings set forth herein, the Parties hereto hereby agree as follows:

 

ARTICLE
1

VOTING
AGREEMENT; GRANT OF PROXY

 

Section 1.01. Voting Agreement.
Each Stockholder hereby agrees to vote (or cause to be voted) all of the Securities, (which such Securities include (i) shares of Common
Stock or voting securities of the Company, (ii) securities of the Company convertible into or exchangeable for shares of Common Stock
or voting securities of the Company or (iii) options or other rights to acquire from the Company any Common Stock, voting securities or
securities convertible into or exchangeable for Common Stock or voting securities of the Company), which such Stockholder has the right
to so vote at the Stockholder Meeting in favor of the approval and adoption Transactions and any actions required in furtherance thereof.
In addition, from the date hereof and until the termination of this Agreement each Stockholder hereby agrees to vote (or cause to be voted)
at any annual, special or other meeting of the stockholders of the Company, and at any adjournment or adjournments thereof, or pursuant
to any consent in lieu of a meeting or otherwise, all of the Securities which such Stockholder has the right to so vote:

 

	 	a)	against
    any action or agreement that would reasonably be expected to result in a breach in any material respect of any covenant, representation
    or warranty or any other obligation of the Company under the Purchase Agreement;
	 	 	 
	 	b)	against
    any action that might impede, frustrate, interfere with, delay, postpone or adversely affect the Transactions, Transaction Documents
    or the constitutive documents of the Company (including the articles of incorporation and bylaws of the Company) that would materially
    and adversely affect the rights of the Management Team; and 
	 	 	 
	 	c)	against
    any action that might impede, frustrate, interfere with, delay, postpone or adversely affect the rights of the Management Team under
    Section 2.01 of the Stockholders Agreement. 

 

    	 

     

    

 

Any
vote required to be cast or consent required to be executed pursuant to this Section 1.01 shall be cast or executed in accordance with
the applicable procedures related thereto so as to ensure that it is duly counted for purposes of determining that a quorum is present
(if applicable) and for purposes of recording the results of that vote or consent; and if any action is taken by written consent rather
than at a meeting of the stockholders of the Company, consent shall be given or withheld by each Stockholder with respect to the Securities
held by such Stockholder in the same manner as if such Securities were voted at a meeting in accordance with the provisions of Section
1.01.

 

Section
1.02. Irrevocable Proxy. In furtherance of each Stockholder’s agreement in Section 1.01 above, each Stockholder hereby
irrevocably grants to, and appoints, Parent and any designee thereof and each of Parent’s officers, as such Stockholder’s
attorney, agent and proxy (such grants and appointment, the “Irrevocable Proxy”), with full power of substitution, to vote
and otherwise act with respect to all of such Stockholder’s Securities at any meeting of the stockholders of the Company (whether
annual or special and whether or not an adjourned or postponed meeting), and in any action by written consent of the shareholders of
the Company, on the matters and in the manner specified in Section 1.01. THIS PROXY AND POWER OF ATTORNEY ARE IRREVOCABLE (UNTIL THE
TWO YEAR ANNIVERSAIRY OF THE CLOSING) AND COUPLED WITH AN INTEREST SUFFICIENT IN LAW TO SUPPORT AN IRREVOCABLE PROXY AND, TO THE EXTENT
PERMITTED UNDER APPLICABLE LAW, SHALL BE VALID AND BINDING ON ANY PERSON TO WHOM SHAREHOLDER MAY TRANSFER ANY OF ITS SECURITIES IN BREACH
OF THIS AGREEMENT. Each Stockholder hereby revokes all other proxies and powers of attorney with respect to all of such Stockholder’s
Securities that may have heretofore been appointed or granted, and no subsequent proxy (whether revocable or irrevocable) or power of
attorney shall be given (and if given, shall not be effective) by such Stockholder with respect thereto on the matters covered by Section
1.01. Each Stockholder hereby affirms that the irrevocable proxy set forth in this Section 1.01 is given in connection with the execution
of the Purchase Agreement, and that such irrevocable proxy is given to secure the performance of the duties of such Stockholder under
this Agreement.

 

ARTICLE
2

REPRESENTATIONS
AND WARRANTIES OF EACH STOCKHOLDER

 

Each
Stockholder represents and warrants to the Company:

 

Section
2.01. Authorization. The Stockholder has duly executed and delivered this Agreement, and the execution, delivery and performance
by the Stockholder of this Agreement and the consummation by the Stockholder of the transactions contemplated hereby are within the powers
and legal capacity of the Stockholder and have been duly authorized by all necessary action. Assuming accuracy of the representation
set forth in Section 3.01, this Agreement is a valid and binding agreement of the Stockholder, enforceable against the Stockholder in
accordance with its terms, except to the extent enforceability may be subject to (i) bankruptcy, insolvency, fraudulent conveyance, reorganization,
moratorium and other similar Laws affecting or relating to creditors’ rights generally and (ii) general equitable principles (whether
considered in a proceeding in equity or at law).

 

Section
2.02. Non-Contravention. The execution, delivery and performance by the Stockholder of this Agreement and the consummation of
the transactions contemplated hereby do not and will not (i) violate any law, rule, regulation, judgment, injunction, order or decree
applicable to the Stockholder, (ii) require any consent or other action by any Person under, constitute a default under, or give rise
to any right of termination, cancellation or acceleration or to a loss of any benefit to which the Stockholder is entitled in respect
of the Securities under any provision of any agreement or other instrument binding on the Stockholder or (iii) result in the imposition
of any Lien on any of the Securities (other than the Lien created hereunder).

 

    	 

     

    

 

ARTICLE
3

REPRESENTATIONS
AND WARRANTIES OF THE COMPANY

 

The
Company represents and warrants to each Stockholder:

 

Section
3.01. Authorization. The Company has duly executed and delivered the Purchase Agreement and this Agreement, and the execution,
delivery and performance by the Company of the Purchase Agreement and this Agreement and the consummation by the Company of the Transactions
and actions contemplated thereby and hereby are within the corporate powers of the Company and have been duly authorized by all necessary
corporate action. Each of the Purchase Agreement and this Agreement constitutes a valid and binding agreement of the Company, enforceable
against the Company in accordance with its terms, except to the extent enforceability may be subject to (i) bankruptcy, insolvency, fraudulent
conveyance, reorganization, moratorium and other similar Laws affecting or relating to creditors’ rights generally and (ii) general
equitable principles (whether considered in a proceeding in equity or at law).

 

ARTICLE
4

COVENANTS
OF EACH STOCKHOLDER

 

Each
Stockholder hereby covenants and agrees that so long as this Agreement is in effect:

 

Section
4.01. No Proxies for or Encumbrances on Securities. Except pursuant to the terms of this Agreement and the Purchase Agreement,
the Stockholder shall not, without the prior written consent of each Party of this Agreement, directly or indirectly, grant any proxies
or enter into any voting trust or other agreement or arrangement with respect to the voting of any of the Securities. The Stockholder
shall not seek or solicit any such assignment, encumbrance or other arrangement or understanding and agrees to notify the Company promptly,
and to provide all details requested by the Company, if the Stockholder shall be approached or solicited, directly or indirectly, by
any Person with respect to any of the foregoing.

 

ARTICLE
5

MISCELLANEOUS

 

Section
5.01. Further Assurances. The Company and the Stockholder will each execute and deliver, or cause to be executed and delivered,
all further documents and instruments and use its best efforts to take, or cause to be taken, all actions and to do, or cause to be done,
all things necessary, proper or advisable under applicable laws and regulations, to consummate and make effective the transactions contemplated
by this Agreement.

 

Section
5.02. Amendments; Termination. Any provision of this Agreement may be amended or waived if, but only if, such amendment or waiver
is in writing and is signed, in the case of an amendment, by each party to this Agreement or in the case of a waiver, by the party against
whom the waiver is to be effective. This Agreement shall continue in full force and effect until such date that is six months following
the Effective Date upon which date all rights and obligations of the parties under this Agreement shall immediately terminate, except
as provided in Section 5.12 hereof.

 

Section
5.03. Expenses. All costs and expenses incurred in connection with this Agreement shall be paid by the party incurring such cost
or expense.

 

Section
5.04. Successors and Assigns; Obligations of Each Stockholder. The provisions of this Agreement shall be binding upon and inure
to the benefit of the parties hereto and their respective successors and assigns; provided that no party may assign, delegate
or otherwise transfer any of its rights or obligations under this Agreement without the consent of the other parties hereto.

 

    	 

     

    

 

Section
5.05. Governing Law; Venue. This Agreement shall be governed by and construed and enforced in accordance with the laws of the
State of Delaware without regard to the principles of conflicts of laws. The parties hereby irrevocably submit to the jurisdiction of
the courts of the State of Delaware and the federal courts located in the State of Delaware in respect of the interpretation and enforcement
of the provisions of this Agreement.

 

Section
5.06. Entire Agreement. This Agreement, together with the Purchase Agreement and other documents incorporated therein, appended
thereto or contemplated thereby, constitutes the complete, final and exclusive statement of the agreement between the parties pertaining
to the subject matter hereof and supersedes all prior agreements, understandings, negotiations and discussions, whether oral or written,
of the parties.

 

Section
5.07. Counterparts; Effectiveness. This Agreement may be signed in any number of counterparts, each of which shall be an original,
with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement shall become effective as
between the Company, on the one hand, and the Stockholder, on the other hand, when each such party shall have received counterparts hereof
signed by each such other party.

 

Section
5.08. Severability. If any term, provision or covenant of this Agreement is held by a court of competent jurisdiction or other
authority to be invalid, void or unenforceable, the remainder of the terms, provisions and covenants of this Agreement shall remain in
full force and effect and shall in no way be affected, impaired or invalidated.

 

Section
5.09. Specific Performance. The parties hereto agree that the Company would suffer irreparable damage in the event any provision
of this Agreement is not performed in accordance with the terms hereof and that the parties shall be entitled to specific performance
of the terms hereof in addition to any other remedy to which they are entitled at law or in equity.

 

Section
5.10. Capitalized Terms. Capitalized terms used but not defined herein shall have the respective meanings set forth in the Purchase
Agreement.

 

Section
5.11. Notices. Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be
effective (a) when personally delivered or transmitted by electronic means, such as electronic mail, on a business day during normal
business hours where such notice is to be received at the address or number designated below, (b) on the business day when verification
of delivery is obtained when sent by fully paid overnight courier, or (c) on the business day that is three (3) days following the date
of mailing by courier, fully prepaid, addressed to such address, whichever shall first occur. The addresses for such communications shall
be:

 

	If
    to the Company or the Management Team:	 
	 	 
	With
    a copy to (which shall not constitute notice):	 
	 	 
	If
    to the Majority Stockholders:	 

 

Any
Party hereto may from time to time change its address for notices under this Section 5.11 by giving at least five (5) days’ notice
of such changed address to the other Party hereto.

 

Section
5.12. Stockholder Capacity. Each Stockholder signs solely in the Stockholder’s capacity as the record holder or beneficial
owner of the Securities and nothing in this Agreement shall limit or affect any actions taken by the Stockholder in the Stockholder’s
capacity as an officer or director of the Company. This Section 5.12 shall survive termination of this Agreement.

 

[Remainder
of this page is intentionally blank]

 

    	 

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the day and year first above written.

 

	 	JUPITER
    WELLNESS, INC.
	 	 	 
	 	By:	/s/
    Brian John
	 	Name:	Brian
    John
	 	Title:	Chief
    Executive Officer
	 	 	 
		STOCKHOLDERS:
    
	 	 
	 	By:	/s/
    Brian John
	 	Name:	Brian
    John
	 	 	 
	 	By:	/s/
    Ryan Allison
	 	Name:	Ryan
    Allison
	 	 	 
	 	By:	/s/
    Glynn Wilson
	 	Name:	Dr.
    Glynn Wilson
	 	 	 
	 	By:	/s/
    Richard Miller
	 	Name:	Richard
    Miller 
	 	 	 
	 	MAJORITY
    STOCKHOLDERS:
	 	 	 
	 	NEXT
    FRONTIER HOLDINGS, INC.
	 	 	 
	 	By:	/s/
    Shannon Soqui
	 	Name:	Shannon
    Soqui
	 	Title:	Executive
    Chairman
	 	 	 
	 	SUD
    AGARAWL
	 	 	 
	 	By:	/s/
    Sud Agarawl
	 	Name:	Sud
    Agarwal
	 	Title:	ChairmanExhibit
10.3

 

EXECUTION
VERSION

 

CONFIDENTIALITY
AGREEMENT

 

This
Confidentiality Agreement (this “Agreement”) is made and entered into this 7 day of January, 2022 by and between Jupiter
Wellness, Inc., a Delaware corporation (“Jupiter Wellness” or the “Company”), and Next Frontier Pharmaceuticals,
Inc., a Delaware corporation (“Next Frontier Pharmaceuticals”).

 

WHEREAS,
Jupiter Wellness and Next Frontier Pharmaceuticals have been engaging in and are furnishing each other with certain information in connection
with that certain First and Amended Stock Purchase Agreement dated January 7, 2022, by and among Next Frontier Pharmaceuticals,
the listed individuals named therein and Jupiter Wellness’s Affiliate (defined below), Jupiter Investments, Inc. (“Jupiter
Investments”, Next Frontier Pharmaceuticals and Jupiter Wellness being sometimes referred to collectively as the “Parties”
and individually as a “Party”) (the “Transaction”); and

 

WHEREAS,
in order to facilitate the consideration and negotiation of the Transaction, each Party has requested access to certain non-public information
regarding the other Party (each Party, in its capacity as a provider of information, is referred to in this Agreement as the “Provider”;
and each Party, in its capacity as a recipient of information, is referred to in this Agreement as the “Recipient”). This
Agreement sets forth the Parties’ obligations regarding the use and disclosure of such information and regarding various related
matters.

 

WHEREAS,
in connection with the evaluation of the Transaction, the parties will be receiving, reviewing, and analyzing certain information which
is confidential, proprietary or otherwise not generally available to the public with respect to the other party’s (including its
Affiliates) business operations and services, the marketing or manufacturing, developing and promotion of products and services, business
policies and practices, technical, financial and strategic information and other matters.

 

NOW,
THEREFORE, The Parties, intending to be legally bound, acknowledge and agree as follows:

 

1.
Limitations on Use and Disclosure of Confidential Information. Other than as specifically provided in Sections 2 and 4 below,
Recipient will not, and will direct the Recipient’s Representatives (as defined in Section 15 below) not to, at any time, directly
or indirectly:

 

(a)
make use of any of the Provider’s Confidential Information (as defined in Section 12 below), except for the specific purpose of
considering, evaluating, negotiating or consummating the Transaction; or

 

(b)
disclose any of the Provider’s Confidential Information to any Person (as defined in Section 15 below), including, for the avoidance
of doubt and without limitation, any Representative of the Recipient unless in compliance with Section 4 below).

 

The
Recipient will be liable and responsible for any breach of this Agreement by any of its Representatives, except that Recipient shall
not be responsible for any breach of this Agreement by those of its Representatives who have otherwise entered into a confidentiality
agreement directly with the Company consistent with the confidentiality provisions of this Agreement.

 

2.
Party Contact. Each of Recipient’s Representatives shall have been directed to abide by the provisions of this Agreement
expressly applicable to Representatives.

 

3.
Intentionally Omitted. 

 

    	 

     

    

 

4.
Permitted Disclosures.

 

(a)
Notwithstanding the limitations set forth in Section 1 above:

 

(i) the
Recipient (and, if applicable, its Representatives) may disclose Confidential Information of the Provider if and to the extent that
the Provider consents in writing to the Recipient’s (or, if applicable, any of its Representative’s) disclosure thereof;

 

(ii)subject to Section 2 and Section 4(b), the Recipient (and, if applicable, its Representatives) may disclose Confidential Information
of the Provider to any Representative of the Recipient, but only to the extent such Representative (A) reasonably needs to know such
Confidential Information for the purpose of helping the Recipient consider, evaluate, negotiate or consummate a Transaction, and (B)
has been directed to, and has agreed to, abide by the provisions of this Agreement expressly applicable to Representatives; and

 

(iii)subject to Section 4(c) below, the Recipient (and, if applicable, its Representatives) may disclose Confidential Information of the
Provider to the extent required by any law, rule, or regulation, including in connection with any legal, regulatory, judicial, or
administrative process (including any deposition, interrogatory, oral questioning, information or document request, subpoena, court
order, regulatory filing, civil investigative demand or other similar process) or any audit or inquiry by a regulator, bank examiner
or auditor, self-regulating organization or pursuant to mandatory professional ethics rules (collectively,
“Law”).

 

(b)
If prior to the disclosure of certain Confidential Information, the Provider delivers to the Recipient a written notice stating that
such Confidential Information of the Provider may be disclosed only to specified Representatives of the Recipient (e.g. outside counsel
only), then, notwithstanding anything to the contrary contained in Section 4(a)(ii) above, the Recipient (and, if applicable, such specified
Representatives) will not thereafter disclose or permit the disclosure of any of such designated Confidential Information to any other
Representative of the Recipient.

 

(c)
Notwithstanding the provisions of Section 4(a)(iii), if the Recipient or any of the Recipient’s Representatives is requested
or required by Law to disclose any of the Provider’s Confidential Information to any Person, then the Recipient will, and will
direct its Representatives to, as soon as reasonably practicable, provide the Provider with written notice (email being sufficient)
of the applicable request or requirement so that the Provider may seek, at its sole expense, a protective order or other appropriate
remedy to prevent, limit or delay such disclosure or the nature and scope thereof; provided, that notice to the Provider is
not required if an information request is made by a bank, securities, tax or other regulatory, governmental or supervisory authority
in the course of a routine, ordinary course examination of Recipient’s or its Representatives’ books and records by such
authority, or in response to any request by such authority that is not targeted at the Confidential Information, Provider or the
Transaction. The Recipient will, and will direct its Representatives to, fully cooperate with the Provider and the Provider’s
Representatives, at the Provider’s sole expense, in any attempt by the Provider to obtain any such protective order or other
remedy, except to the extent that such efforts involve litigation against the Recipient or any of its Representatives. In the
absence of such protective order or other remedy in connection with any request or requirement that the Recipient or any of its
Representatives, as applicable and as required by Law, disclose Confidential Information of the Provider, the Recipient or such
Representative receives advice from legal counsel confirming that the disclosure of such Confidential Information is required by
Law, then the Recipient or any such Representatives, as applicable and as required by Law, may disclose such Confidential
Information solely to the extent required by Law; provided, however, that the Recipient and its Representatives will
fully cooperate with the Provider’s efforts, at the Provider’s sole expense, to ensure that such Confidential
Information is treated confidentially by each Person to whom it is disclosed.

 

5.
Return of Confidential Information. Upon receipt of the Provider’s written request, the Recipient will, and will direct
the Recipient’s Representatives to, promptly deliver to the Provider or destroy, at the Provider’s option, any of the Provider’s
Confidential Information (and all copies thereof) obtained or possessed by the Recipient or any of the Recipient’s Representatives.
Notwithstanding the delivery to the Provider (or the destruction by the Recipient) of Confidential Information of the Provider pursuant
to this Section 5, the Recipient and its Representatives will continue to be bound by their confidentiality obligations and other obligations
under this Agreement for the term of this Agreement. In addition, notwithstanding this Section 5, (i) Recipient and its Representatives
may retain secured copies of the Provider’s Confidential Information solely to the extent required to comply with Law, legal or
regulatory requirements, established document retention policies or demonstrate compliance with this Agreement, (ii) Recipient and its
Representatives shall not be required to destroy any computer files stored securely by them that are created during automatic system
back-up and shall be entitled to retain such Confidential Information as they are required to retain by Law or any professional standard
applicable to them (any such retained Confidential Information pursuant to clauses (i) through (ii), “Retained Confidential Information”).

 

    	 

     

    

 

6.
Limitation on Soliciting Employees and Distributors. During the twelve (12) month period commencing on the date of this Agreement,
Next Frontier Pharmaceuticals will not, directly or indirectly solicit, induce, encourage or attempt to solicit, induce or encourage
any Covered Person (as defined herein) to terminate such Covered Person’s relationship with the other Party in order to become
an employee, consultant, distributor or independent contractor, to or for Next Frontier Pharmaceuticals; provided, however,
that the foregoing provision will not be deemed to prevent (a) Next Frontier Pharmaceuticals or its Representatives from conducting bona
fide general solicitations of employment published in a journal, newspaper or other publication of general circulation or in trade publications
or other similar media or through the use of search firms or the internet and which, in any case, are not directed specifically toward
the Company or its employees or (b) the employment of any such Person (i) if such Person first approaches Next Frontier Pharmaceuticals
on an unsolicited basis or (ii) following cessation of such Person’s employment with the Company without any prior solicitation
or encouragement by Next Frontier Pharmaceuticals in violation of this Agreement. For purposes of this Agreement, “Covered Person”
shall mean any Person who is a manager or executive employee of the Company as of the date of this Agreement or who becomes a manager
or executive employee of the Company before the termination of discussions regarding a Transaction, and either (i) with whom Next Frontier
Pharmaceuticals has direct interaction during discussions and negotiations regarding the Transaction or (ii) about whom the Company has
provided Confidential Information to Next Frontier Pharmaceuticals in advance of any solicitation by Next Frontier Pharmaceuticals (other
than basic employee census data or other generalized information).

 

7.
Limitation on Soliciting Customers, Vendors and Suppliers. During the twelve (12) month period commencing on the date of this
Agreement, Next Frontier Pharmaceuticals will not (a) directly or indirectly solicit, induce, encourage or attempt to solicit, induce
or encourage any known customer of, vendor or supplier to the Company to cease or materially alter its relationship with the Company,
nor (b) contact any known customer of, vendor or supplier to the Company regarding any of the Company’s Confidential Information
or a Transaction; provided, however, the covenants contained in this Agreement shall not limit any contacts made by Next
Frontier Pharmaceuticals or its Representatives (i) in respect of such Persons in the ordinary course of business consistent with past
practice (ii) in the course of conducting commercial or market due diligence in connection with a Transaction on a no-names basis with
the prior consent of Provider or (iii) with Representatives (acting in their capacity as such).

 

8.
Intentionally Omitted. 

 

9.
No Waiver. No failure or delay by either Party or any of its Representatives in exercising any right, power or privilege under
this Agreement will operate as a waiver thereof, and no single or partial exercise of any such right, power or privilege will preclude
any other or future exercise thereof or the exercise of any other right, power or privilege under this Agreement. No provision of this
Agreement can be waived or amended except by means of a written instrument that is validly executed on behalf of both of the Parties
and that refers specifically to the particular provision or provisions being waived or amended.

 

10.
Remedies. Each Party acknowledges that money damages may not be a sufficient remedy for any breach of this Agreement by such
Party or by any of such Party’s Representatives and that the other Party may suffer irreparable harm as a result of any such breach.
Accordingly, each Party will also be entitled to equitable relief, including injunction and specific performance, as a remedy for any
breach or threatened breach of this Agreement by the other Party or any of the other Party’s Representatives. The equitable remedies
referred to above will not be deemed to be the exclusive remedies for a breach of this Agreement, but rather will be in addition to all
other remedies available at law or in equity to the Parties.

 

11.
Successors and Assigns; Applicable Law; Jurisdiction and Venue. Neither Party may assign its rights or obligations hereunder
without the prior written consent of the other Party; provided, however, that a Provider may assign its rights hereunder
to any acquiror of or other successor in interest to the Provider. This Agreement will be governed by and construed in accordance with
the laws of the State of Delaware (without giving effect to principles of conflicts of laws). Each Party and its Representatives: (a)
irrevocably and unconditionally consent and submit to the jurisdiction of the state and federal courts located in the County of Newcastle
in the State of Delaware for purposes of any action, suit or proceeding arising out of or relating to this Agreement; (b) agree that
service of any process, summons, notice or document by U.S. registered mail to the address and email addresses set forth at the end of
this Agreement shall be effective service of process for any action, suit or proceeding brought against such Party or any of such Party’s
Representatives; (c) irrevocably and unconditionally waive any objection to the laying of venue of any action, suit or proceeding arising
out of or relating to this Agreement in any state or federal court located in the County of Newcastle in the State of Delaware; and (d)
irrevocably and unconditionally waive the right to plead or claim, and irrevocably and unconditionally agree not to plead or claim, that
any action, suit or proceeding arising out of or relating to this Agreement that is brought in any state or federal court located in
the County of Newcastle in the State of Delaware has been brought in an inconvenient forum.

 

    	 

     

    

 

12.
Confidential Information. For purposes of this Agreement, the Provider’s “Confidential Information” will
be deemed to include:

 

(a)
any information (including, without limitation, any technology, know-how, patent application, test result, research study, business
plan, budget, forecast or projection) relating directly or indirectly to the business of the Provider, any predecessor entity or any
subsidiary or other Affiliate of the Provider (whether prepared by the Provider or by any other Person and whether or not in written
form) that is or has been made available to the Recipient or any Representative of the Recipient by or on behalf of the Provider or any
Representative of the Provider on or after the date hereof in connection with the consideration, evaluation or negotiation of a Transaction;

 

(b)
such portion of any memorandum, analysis, compilation, summary, interpretation, study, report or other document, record or material
that is or has been prepared by or for the Recipient or any Representative of the Recipient and that contains, or reflects in any reasonably
apparent manner any information of the type referred to in clause “(a)” of this Section 12;

 

(c)
the existence and terms of this Agreement, and the fact that information of the type referred to in clause “(a)” of this
Section 12 has been made available to the Recipient or any of its Representatives; and

 

(d)
the fact that discussions or negotiations are or may be taking place with respect to a Transaction involving the Parties, and the
proposed terms of any such Transaction.

 

However,
the Provider’s “Confidential Information” will not be deemed to include:

 

any
information that is or becomes generally available to the public or generally known in the industry in which the Company operates other
than as a direct or indirect result of the disclosure of any of such information by the Recipient or by any of the Recipient’s
Representatives in breach of this Agreement;

 

any
information that was in the Recipient’s or any of its Representatives’ possession prior to the time it was first made available
to the Recipient or any of the Recipient’s Representatives by or on behalf of the Provider or any of the Provider’s Representatives,
provided that the source of such information was not and is not known by the Recipient to be bound by any contractual or other
obligation of confidentiality, directly or indirectly, to the Provider with respect to any of such information;

 

any
information that is or becomes available to the Recipient or any of its Representatives’ on a non-confidential basis from a source
other than the Provider or any of the Provider’s Representatives, provided that such source is not known by the Recipient
to be bound by any contractual or other obligation of confidentiality, directly or indirectly, to the Provider with respect to any of
such information; or

 

is
or was independently developed by the Recipient or its Representatives with no use of Confidential Information.

 

13.
Trading in Securities. Next Frontier Pharmaceuticals acknowledges and agrees that it is aware (and that the its Representatives are
aware or will be advised by Next Frontier Pharmaceuticals) that Confidential Information being furnished by the Company contains material,
non-public information regarding the Company and that the United States securities laws prohibit any Person who has such material, non-public
information from purchasing or selling securities of the Company on the basis of such information or from communicating such information
to any Person under circumstances in which it is reasonably foreseeable that such Person is likely to purchase or sell such securities
on the basis of such information.

 

    	 

     

    

 

14.
Standstill. In an event that the Transaction has not been consummated, Next Frontier Pharmaceuticals agrees that, for a period of
twelve (12) months from the date of this Agreement, unless specifically invited in writing by the board of directors of the Company,
neither Next Frontier Pharmaceuticals nor any Person with whom Next Frontier Pharmaceuticals may be deemed to be acting in concert, will
in any manner, directly or indirectly: (a) effect or seek, offer or propose (whether publicly or otherwise) to effect, or announce any
intention to effect or cause or participate in or in any way assist, facilitate or encourage any other Person to effect or seek, offer
or propose (whether publicly or otherwise) to effect or participate in, (i) any acquisition of any securities (or beneficial ownership
thereof), or rights or options to acquire any securities (or beneficial ownership thereof), or any assets, indebtedness or businesses
of the Company or any of its subsidiaries, (ii) any tender or exchange offer, merger or other business combination involving the Company
or, any of the subsidiaries or assets of the Company constituting a significant portion of the consolidated assets of the Company and
its subsidiaries, (iii) any recapitalization, restructuring, liquidation, dissolution or other extraordinary transaction with respect
to the Company or any of its subsidiaries, or (iv) any “solicitation” of “proxies” (as such terms are used in
the proxy rules of the Securities and Exchange Commission) or consents to vote any voting securities of the Company; (b) form, join or
in any way participate in a “group” (as defined under the Securities Exchange Act of 1934, as amended (the “1934 Act”))
with respect to the Company or otherwise act in concert with any Person in respect of any such securities; (c) otherwise act, alone or
in concert with others, to seek representation on or to control or influence the management, board of directors or policies of the Company
or to obtain representation on the board of directors of the Company; (d) take any action which would or would reasonably be expected
to force the Company to make a public announcement regarding any of the types of matters set forth in (a) above; or (e) enter into any
discussions or arrangements with any third party with respect to any of the foregoing. Next Frontier Pharmaceuticals also agrees during
such period not to request (in any manner that would reasonably be likely to cause the Company to disclose publicly) that the Company
or any of its Representatives, directly or indirectly, amend or waive any provision of this paragraph (including this sentence); provided,
that in the event that the Company or any of its subsidiaries issues any securities after the date hereof, the Company shall, as soon
as reasonably practicable, provide Next Frontier Pharmaceuticals notice of such issuance so that Next Frontier Pharmaceuticals may seek
to comply with the terms of this Section 14 that are applicable to such newly issued securities. The term “securities”, as
used in this Agreement, shall include, without limitation, any securities of the Company and any derivative, swap or other transaction
the purpose or effect of which is to give Next Frontier Pharmaceuticals or any Person with whom Next Frontier Pharmaceuticals may be
deemed to be acting in concert, economic risk similar to ownership of shares of any class or series of the Company, including due to
the fact that the value of such derivative, swap or other transaction is determined by reference to the price, value or volatility of
any shares of any class or series of the Company, or which derivative, swap or other transaction provides, directly or indirectly, the
opportunity to profit from any increase in the price or value of shares of any class or series of the Company.

 

15.
Miscellaneous.

 

(a)
For purposes of this Agreement, a Party’s “Representatives” will be deemed to include each Person that is or during
the term of this Agreement becomes (i) a subsidiary or other Affiliate of such Party, or (ii) an officer, director, member, manager,
executive partner, employee, partner, advisor (including without limitation accountants, attorneys, financial advisors and consultants),
agent or other representative, of such Party or of any of such Party’s subsidiaries or other Affiliates, or (iii) only upon prior
written approval of other Party, any debt financing source to be used in connection with a potential Transaction; provided, that
the term “Representatives” shall only include those who actually receive Confidential Information from Recipient or one of
Recipient’s other Representatives or otherwise in connection with Recipient’s consideration of a Transaction.

 

(b)
The term “Person,” as used in this Agreement, will be broadly interpreted to include any individual and any corporation,
partnership, entity, group, tribunal or governmental authority.

 

(c)
The term “Affiliate” has the meaning given to it under the 1934 Act.

 

(d)
The bold-faced captions appearing in this Agreement have been included only for convenience and shall not affect or be taken into
account in the interpretation of this Agreement.

 

    	 

     

    

 

(e)
Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the
validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the offending term or provision
in any other situation or in any other jurisdiction.

 

(e)
By making Confidential Information or other information available to the Recipient or the Recipient’s Representatives, the
Provider is not, and shall not be deemed to be, granting (expressly or by implication) any license or other right under or with respect
to any patent, trade secret, copyright, trademark or other proprietary or intellectual property right.

 

(f)
To the extent that any Confidential Information includes materials or other information that may be subject to the attorney-client
privilege, work product doctrine or any other applicable privilege or doctrine concerning any pending, threatened or prospective action,
suit, proceeding, investigation, arbitration or dispute, it is acknowledged and agreed that the Parties have a commonality of interest
with respect to such action, suit, proceeding, investigation, arbitration or dispute and that it is their mutual desire, intention and
understanding that the sharing of such materials and other information is not intended to, and shall not, affect the confidentiality
of any of such materials or other information or waive or diminish the continued protection of any of such materials or other information
under the attorney-client privilege, work product doctrine or other applicable privilege or doctrine. Accordingly, all Confidential Information
that is entitled to protection under the attorney-client privilege, work product doctrine or other applicable privilege or doctrine shall
remain entitled to protection thereunder and shall be entitled to protection under the joint defense doctrine, and the Parties agree
to take reasonable measures necessary to preserve, to the fullest extent possible, the applicability of all such privileges or doctrines.

 

(g)
This Agreement constitutes the entire agreement between the Recipient and the Provider regarding the subject matter hereof and supersedes
any prior agreement between the Recipient and the Provider regarding the subject matter hereof. This Agreement also applies to Confidential
Information accessed through any electronic data room made available in connection with a Transaction and supersedes any “click
through” acknowledgement or agreement associated with any such electronic data room.

 

(h)
This Agreement may be executed in several counterparts, each of which shall constitute an original and all of which, when taken together,
shall constitute one agreement. The exchange of a fully executed Agreement (in counterparts or otherwise) by electronic transmission
or by facsimile shall be sufficient to bind the parties to the terms and conditions of this Agreement.

 

(i)
This Agreement shall expire and cease to have any force or effect on the earlier of (i) the eighteen (18) month anniversary of the
date hereof and (ii) the date the Transaction is consummated; provided, however, that (A) with respect to any Retained
Confidential Information retained pursuant to Section 5 of this Agreement, each Party will and will direct its Representatives to continue
to undertake all necessary precautions (consistent with the precautions such Party or such Representative ordinarily takes to safeguard
its own confidential information) to keep such Retained Confidential Information confidential for the term of this Agreement; and (B)
the termination of this Agreement shall not relieve any Party from any liability with respect to any violation or breach of any provision
contained in this Agreement.

 

Signature
page follows

 

    	 

     

    

 

	 	Jupiter
    Wellness, Inc.
	 	 	 
	 	By:	/s/
                                            Brian John

	 	Name:	Brian
    S. John 
	 	Title:	Chief
    Executive Officer

 

	 	Next
    Frontier Pharmaceuticals, Inc. 
	 	 	 
	 	By:	/s/
                                            Shannon Soqui

	 	Name:	Shannon
    Soqui
	 	Title:	Chief
    Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}]]